FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to the field of biotechnology and medicine. The present invention discloses a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify BoNT binding to the receptor. Specific mutations and combinations of mutations are also described. Also disclosed are isolated modified nucleic acids, chimeric molecules, pharmaceutical compositions and methods for their preparation and use.
EFFECT: invention relates to one of the promising directions in the development of new methods of treatment of a number of diseases.
20 cl, 3 tbl, 1 ex, 21 dwg
| Title |
Year |
Author |
Number |
| CONSTRUCTED BOTULINUM NEUROTOXIN |
2017 |
|
RU2789302C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID |
2019 |
- Stenmark, Pal
- Masuyer, Geoffrey
|
RU2816855C2 |
| TREATMENT OF SKIN DISEASES |
2021 |
- Maignel, Jacquie
- Krupp, Johannes
|
RU2840027C1 |
| NON-TOXIC POLYPEPTIDES OF CLOSTRIDIAL NEUROTOXIN FOR USE IN TREATING NEUROLOGICAL DISORDERS |
2020 |
- Fonfria Subiros, Elena
- Lewandowska, Agnieszka
|
RU2839368C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES |
2018 |
|
RU2719164C1 |
| HYBRID NEUROTOXINS |
2017 |
- Fonfria Subiros, Elena
- Burgin, David
|
RU2782382C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES |
2019 |
|
RU2727402C1 |
| MODIFIED BOTULINUM NEUROTOXIN FOR TREATING EXTREMITY SPASTICITY |
2021 |
- Grigore, Nicolae
- Ruffle, Katie
- Picaut, Philippe
|
RU2841585C1 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM |
2019 |
|
RU2800604C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS |
2020 |
- Ojler, Dzhordzh E.
- Gertts, Barri
|
RU2824389C2 |
